Compare OcuNexus Therapeutics vs Lead Pharma
Customers evaluate the quality of OcuNexus Therapeutics's products using the following success metrics.
OcuNexus Therapeutics is 19 yrs old and is based in United States.
OcuNexus Therapeutics is a clinical-stage company focused on the healthcare sector, specifically in the development of treatments for diseases where the inflammasome pathway of inflammation is dysregulated. The company's main product is a small molecule, administered orally once a day, that targets the pathologically open Connexin43 Hemichannel, which is responsible for inflammasome mediated autoinflammation in several disease states. The company primarily sells to the ophthalmology and nephrology sectors, with a focus on conditions such as diabetic retinopathy, diabetic nephropathy, and the intermediate stage of macular degeneration. OcuNexus Therapeutics was formerly known as CoDa Therapeutics. It was founded in 2005 and is based in San Diego, California.
Lead Pharma is based in Netherlands
Lead Pharma is a clinical-stage pharmaceutical research and development company, operating in the healthcare and pharmaceutical industry. The company's main focus is on designing and developing innovative small-molecule therapies, primarily aimed at treating autoimmune diseases and cancer. Lead Pharma primarily serves the healthcare sector, with a particular emphasis on the pharmaceutical industry. It is based in Oss, Netherlands.
Frans van den Berg (Chief Executive Officer)
Information not available because OcuNexus Therapeutics has not claimed their profile.
Work for OcuNexus Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for OcuNexus Therapeutics?
Claim your profile now.
Why Lead Pharma beats OcuNexus Therapeutics
- Technical experttise
- Unique characteristics
Pipelines products in oncology or immunology
Innovative new small molecule in oncology or immunology
Why They Buy